Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Patterns of minimal residual disease trajectories in 323 newly diagnosed patients with multiple myeloma and correlation with progression-free survival

View Full Paper
Ask AI
Bookmark
Share

Authors

INIoannis Ntanasis-StathopoulosNKNikolaos KanelliasDFDespina Fotiou

Discussion

Loading...

Member takes

Overview

Retrospective analysis links minimal residual disease status to progression-free survival in newly diagnosed multiple myeloma patients, suggesting implications for treatment strategies.

Key Points

  • This research aims to investigate the relationship between minimal residual disease status and progression-free survival in patients with newly diagnosed multiple myeloma.
  • Retrospective study involving 323 newly diagnosed multiple myeloma patients
  • Assessment of minimal residual disease using the Euroflow technique
  • Group comparison of patient outcomes based on MRD status and treatment interventions
  • Median progression-free survival for the cohort was 22.6 months
  • Sustained MRD negativity was linked to superior progression-free survival compared to other groups
  • Presence of even one MRD positive result was associated with inferior progression-free survival outcomes

Cite This Study

Ntanasis-Stathopoulos et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7e7https://doi.org/10.1182/blood-2025-2216
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Minimal residual disease dynamics in newly diagnosed multiple myeloma and impact on progression-free survival: A cohort study.2026
  2. 2Measurable residual disease in newly diagnosed multiple myeloma: Experience from a large cohort from an academic medical center2025
  3. 3Prognostic significance of dynamic minimal residual disease trajectories in newly diagnosed multiple myeloma2026
  4. 4Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma2024 · 14 citations
  5. 5Long term follow up of multiple myeloma patients achieving MRD negativity at 10 <sup>-6</sup> .2026